{"DataElement":{"publicId":"7155055","version":"1","preferredName":"Disease or Disorder Best Outcome of Therapy Myeloproliferative Neoplasm Status Type","preferredDefinition":"A description of the best response to therapy for myeloproliferative neoplasm.","longName":"2946463v1.0:7153995v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2946463","version":"1","preferredName":"Disease or Disorder Best Outcome of Therapy","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Having the most positive qualities._The result of therapy for a given disease or condition in a patient or group of patients.","longName":"2404658v1.0:3194600v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2404658","version":"1","preferredName":"Diseases and Disorders","preferredDefinition":"A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"005AD6E5-0651-6A35-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-09-09","endDate":null,"createdBy":"PWEST","dateCreated":"2005-09-09","modifiedBy":"ONEDATA","dateModified":"2005-09-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3194600","version":"1","preferredName":"Best Outcome of Therapy","preferredDefinition":"Having the most positive qualities.:The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C25432:C18919","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Best","conceptCode":"C25432","definition":"Having the most positive qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Outcome of Therapy","conceptCode":"C18919","definition":"The result of therapy for a given disease or condition in a patient or group of patients.","evsSource":"CTCAE_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D80CD45-BE7A-5B19-E040-BB89AD430E80","latestVersionIndicator":"Yes","beginDate":"2011-03-02","endDate":null,"createdBy":"ZHANGW","dateCreated":"2011-03-02","modifiedBy":"ONEDATA","dateModified":"2011-03-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"747EBAC6-25E8-A734-E040-BB89AD43588E","latestVersionIndicator":"Yes","beginDate":"2009-09-26","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-09-26","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7153995","version":"1","preferredName":"Myeloproliferative Neoplasm Status Type","preferredDefinition":"A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)_A condition or state at a particular time._Something distinguishable as an identifiable class based on common qualities.","longName":"7153995v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Continued complete clinical remission (CCR)","valueDescription":"Continued complete clinical remission","ValueMeaning":{"publicId":"7153996","version":"1","preferredName":"Continued complete clinical remission","longName":"7153996","preferredDefinition":"For recipients already in CR prior to the start of the preparative regimen.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D36FB99-BA7C-36DA-E053-F662850A2068","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D36FB99-BA95-36DA-E053-F662850A2068","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","deletedIndicator":"No"},{"value":"Not assessed","valueDescription":"NOT ASSESSED","ValueMeaning":{"publicId":"2559594","version":"1","preferredName":"NOT ASSESSED","longName":"2559594","preferredDefinition":"Indicates that an assessment was not performed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Assessed","conceptCode":"C139527","definition":"Indicates that an assessment was not performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-B5D7-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2002-02-13","endDate":null,"createdBy":"SBR","dateCreated":"2002-02-13","modifiedBy":"MMADDINENI","dateModified":"2024-02-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D36FB99-BA9F-36DA-E053-F662850A2068","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","deletedIndicator":"No"},{"value":"Progression to AML","valueDescription":"Disease Progression Acute Myeloid Leukemia","ValueMeaning":{"publicId":"4746340","version":"1","preferredName":"Disease Progression Acute Myeloid Leukemia","longName":"4746340","preferredDefinition":"The worsening of a disease over time.: A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise categorized. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease Progression","conceptCode":"C17747","definition":"A process that manifests as the worsening of a disease over time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"11814A91-B4C0-F981-E050-BB89AD4341B2","latestVersionIndicator":"Yes","beginDate":"2015-03-17","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2015-03-17","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9D36FB99-BAB7-36DA-E053-F662850A2068","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","deletedIndicator":"No"},{"value":"Relapse","valueDescription":"IWG-MRT Myelofibrosis Relapse","ValueMeaning":{"publicId":"7158669","version":"1","preferredName":"IWG-MRT Myelofibrosis Relapse","longName":"7158669","preferredDefinition":"No longer meeting criteria for at least clinical improvement after achieving complete response partial response or clinical improvement or loss of anemia response persisting for at least 1 month or loss of spleen response persisting for at least 1 month (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IWG-MRT Myelofibrosis Relapse","conceptCode":"C168642","definition":"No longer meeting criteria for at least clinical improvement after achieving complete response partial response or clinical improvement or loss of anemia response persisting for at least 1 month or loss of spleen response persisting for at least 1 month (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DAEF835-E37E-09CA-E053-F662850A26A4","latestVersionIndicator":"Yes","beginDate":"2020-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-02-03","modifiedBy":"ONEDATA","dateModified":"2020-02-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9DAEF835-E397-09CA-E053-F662850A26A4","beginDate":"2020-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-02-03","modifiedBy":"ONEDATA","dateModified":"2020-02-03","deletedIndicator":"No"},{"value":"Progressive disease","valueDescription":"IWG-MRT Myelofibrosis Progressive Disease","ValueMeaning":{"publicId":"7158670","version":"1","preferredName":"IWG-MRT Myelofibrosis Progressive Disease","longName":"7158670","preferredDefinition":"Appearance of a new splenomegaly that is palpable at least 5 cm below the left costal margin or a greater than or equal to 100 percent increase in palpable distance below left costal margin for baseline splenomegaly of 5 to 10 cm or A 50 percent increase in palpable distance below left costal margin for baseline splenomegaly of greater than 10 cm or Leukemic transformation confirmed by a bone marrow blast count of greater than or equal to 20 percent or a peripheral blood blast content of greater than or equal to 20 percent associated with an absolute blast count of greater than or equal to 1x10^9/L that lasts for at least 2 weeks (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IWG-MRT Myelofibrosis Progressive Disease","conceptCode":"C168645","definition":"Appearance of a new splenomegaly that is palpable at least 5 cm below the left costal margin or A greater than or equal to 100 percent increase in palpable distance, below left costal margin, for baseline splenomegaly of 5 to 10 cm or A 50 percent increase in palpable distance, below left costal margin, for baseline splenomegaly of greater than 10 cm or Leukemic transformation confirmed by a bone marrow blast count of greater than or equal to 20 percent or A peripheral blood blast content of greater than or equal to 20 percent associated with an absolute blast count of greater than or equal to 1x10^9/L that lasts for at least 2 weeks (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD, 22 AUGUST 2013 x VOLUME 122, NUMBER 8)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DAEF835-E3A3-09CA-E053-F662850A26A4","latestVersionIndicator":"Yes","beginDate":"2020-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-02-03","modifiedBy":"ONEDATA","dateModified":"2020-02-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9DAEF835-E3BC-09CA-E053-F662850A26A4","beginDate":"2020-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-02-03","modifiedBy":"ONEDATA","dateModified":"2020-02-03","deletedIndicator":"No"},{"value":"Stable disease (SD)","valueDescription":"IWG-MRT Myelofibrosis Stable Disease","ValueMeaning":{"publicId":"7158671","version":"1","preferredName":"IWG-MRT Myelofibrosis Stable Disease","longName":"7158671","preferredDefinition":"Belonging to none of the above listed response categories (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IWG-MRT Myelofibrosis Stable Disease","conceptCode":"C168644","definition":"Belonging to none of the above listed response categories (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DAEF835-E3C8-09CA-E053-F662850A26A4","latestVersionIndicator":"Yes","beginDate":"2020-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-02-03","modifiedBy":"ONEDATA","dateModified":"2020-02-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9DAEF835-E3E1-09CA-E053-F662850A26A4","beginDate":"2020-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-02-03","modifiedBy":"ONEDATA","dateModified":"2020-02-03","deletedIndicator":"No"},{"value":"Partial clinical remission (PR)","valueDescription":"IWG-MRT Myelofibrosis Partial Remission","ValueMeaning":{"publicId":"7158673","version":"1","preferredName":"IWG-MRT Myelofibrosis Partial Remission","longName":"7158673","preferredDefinition":"Peripheral blood: Hemoglobin greater than or equal to 100 g/L and less than upper normal limit; neutrophil count greater than or equal to 1x10^9/L and less than upper normal limit; platelet count greater than or equal to 100x10^9/L and less than upper normal limit; less than 2 percent immature myeloid cells and Clinical: Resolution of disease symptoms; spleen and liver not palpable; no evidence of extramedullary hematopoiesis or Bone marrow: Age-adjusted normocellularity; less than 5 percent blasts; less than grade 1 myelofibrosis and peripheral blood: Hemoglobin greater than or equal to 85 but less than 100 g/L and less than upper normal limit; neutrophil count greater than 1x10^9/L and less than upper normal limit; platelet count greater than or equal to 50 but less than 100x10^9/L and less than upper normal limit; less than 2 percent immature myeloid cells and Clinical: Resolution of disease symptoms; spleen and liver not palpable; no evidence of extramedullary hematopoiesis(adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IWG-MRT Myelofibrosis Partial Remission","conceptCode":"C168635","definition":"Peripheral blood: Hemoglobin greater than or equal to 100 g/L and less than upper normal limit; neutrophil count greater than or equal to 1x10^9/L and less than upper normal limit; platelet count greater than or equal to 100x10^9/L and less than upper normal limit; less than 2 percent immature myeloid cells and Clinical: Resolution of disease symptoms; spleen and liver not palpable; no evidence of extramedullary hematopoiesis or Bone marrow: Age-adjusted normocellularity; less than 5 percent blasts; less than grade 1 myelofibrosis and peripheral blood: Hemoglobin greater than or equal to 85 but less than 100 g/L and less than upper normal limit; neutrophil count greater than 1x10^9/L and less than upper normal limit; platelet count greater than or equal to 50 but less than 100x10^9/L and less than upper normal limit; less than 2 percent immature myeloid cells and Clinical: Resolution of disease symptoms; spleen and liver not palpable; no evidence of extramedullary hematopoiesis(adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DAEF835-E412-09CA-E053-F662850A26A4","latestVersionIndicator":"Yes","beginDate":"2020-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-02-03","modifiedBy":"ONEDATA","dateModified":"2020-02-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9DAEF835-E42B-09CA-E053-F662850A26A4","beginDate":"2020-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-02-03","modifiedBy":"ONEDATA","dateModified":"2020-02-03","deletedIndicator":"No"},{"value":"Complete clinical remission (CR)","valueDescription":"IWG-MRT Myelofibrosis Complete Remission","ValueMeaning":{"publicId":"7158674","version":"1","preferredName":"IWG-MRT Myelofibrosis Complete Remission","longName":"7158674","preferredDefinition":"Bone marrow: Age-adjusted normocellularity; less than 5 percent blasts; less than or equal to grade 1 myelofibrosis and Peripheral blood: Hemoglobin greater than or equal to 100 g/L and less than upper normal limit; neutrophil count greater than or equal 1x10^9/L and less than upper normal limit; Platelet count greater or equal to 100x10^9/L and less than upper normal limit; less than 2 percent immature myeloid cells and Clinical: Resolution of disease symptoms; spleen and liver not palpable; no evidence of extramedullary hematopoiesis (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IWG-MRT Myelofibrosis Complete Remission","conceptCode":"C168634","definition":"Bone marrow: Age-adjusted normocellularity; less than 5 percent blasts; less than or equal to grade 1 myelofibrosis and Peripheral blood: Hemoglobin greater than or equal to 100 g/L and less than upper normal limit; neutrophil count greater than or equal 1x10^9/L and less than upper normal limit; Platelet count greater or equal to 100x10^9/L and less than upper normal limit; less than 2 percent immature myeloid cells and Clinical: Resolution of disease symptoms; spleen and liver not palpable; no evidence of extramedullary hematopoiesis (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DAEF835-E437-09CA-E053-F662850A26A4","latestVersionIndicator":"Yes","beginDate":"2020-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-02-03","modifiedBy":"ONEDATA","dateModified":"2020-02-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9DAEF835-E450-09CA-E053-F662850A26A4","beginDate":"2020-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-02-03","modifiedBy":"ONEDATA","dateModified":"2020-02-03","deletedIndicator":"No"},{"value":"Clinical improvement (CI)","valueDescription":"IWG-MRT Myelofibrosis Clinical Improvement","ValueMeaning":{"publicId":"7158672","version":"1","preferredName":"IWG-MRT Myelofibrosis Clinical Improvement","longName":"7158672","preferredDefinition":"The achievement of anemia spleen or symptoms response without progressive disease or increase in severity of anemia thrombocytopenia or neutropenia (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"IWG-MRT Myelofibrosis Clinical Improvement","conceptCode":"C168641","definition":"The achievement of anemia spleen or symptoms response without progressive disease or increase in severity of anemia thrombocytopenia or neutropenia (adapted from Revised Response Criteria for Myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. BLOOD 22 AUGUST 2013 x VOLUME 122 NUMBER 8)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9DAEF835-E3ED-09CA-E053-F662850A26A4","latestVersionIndicator":"Yes","beginDate":"2020-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-02-03","modifiedBy":"ONEDATA","dateModified":"2020-02-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A070BE5F-ED88-6FBD-E053-F662850A37E4","beginDate":"2020-02-03","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-03-10","modifiedBy":"ONEDATA","dateModified":"2020-03-10","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008550","version":"1","preferredName":"Disease Response","preferredDefinition":"the response criteria (includes RECIST and others) and associated documentation of disease.","longName":"DZ_RESP","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22C0651-216B-5273-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"7153994","version":"1","preferredName":"Myeloproliferative Neoplasm Status Type","preferredDefinition":"A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008):A condition or state at a particular time.:Something distinguishable as an identifiable class based on common qualities.","longName":"C4345:C25688:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Myeloproliferative Neoplasm","conceptCode":"C4345","definition":"A group of myeloid neoplasms that includes the following: chronic myeloid leukemia, BCR-ABL1 positive; polycythemia vera; essential thrombocythemia;  primary myelofibrosis; chronic neutrophilic leukemia; chronic eosinophilic leukemia, not otherwise specified; and myeloproliferative neoplasm, unclassifiable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D36FB99-BA56-36DA-E053-F662850A2068","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"ONEDATA","dateModified":"2020-01-28","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D36FB99-BA67-36DA-E053-F662850A2068","latestVersionIndicator":"Yes","beginDate":"2020-01-28","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-28","modifiedBy":"MALUMK","dateModified":"2020-05-28","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Compared to the disease status prior to the preparative regimen, what was the best response to HCT or cellular therapy since the date of the last report?","type":"Alternate Question Text","description":"Compared to the disease status prior to the preparative regimen, what was the best response to HCT or cellular therapy since the date of the last report?","url":null,"context":"NHLBI"},{"name":"What was the best response of","type":"Preferred Question Text","description":"What was the best response of myeloproliferative neoplasm to therapy?","url":null,"context":"NHLBI"},{"name":"Best response to line of therapy","type":"Alternate Question Text","description":"Best response to line of therapy","url":null,"context":"NHLBI"},{"name":"Best response to line of therapy","type":"Application Standard Question Text","description":"Best response to line of therapy","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"9D489D93-E54E-4A1D-E053-F662850A2BA0","latestVersionIndicator":"Yes","beginDate":"2020-01-29","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-01-29","modifiedBy":"KUMMEROA","dateModified":"2021-03-19","changeDescription":".System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}